Welcome to SciBX
SciBX: Science-Business eXchange is a weekly publication that unites the scientific acumen of Nature Publishing Group with the business intelligence of BioCentury Publications, Inc. to provide timely, concise, and understandable analysis of the scientific content and commercial potential of the most important translational research papers with the potential to transform human therapeutics and diagnostics.
By distilling the flood of life sciences literature down to the 25 key scientific developments each week, and providing in-depth analysis of the most important findings, SciBX provides a unique scientific and commercial perspective on today's breakthrough science.
Now the SciBX platform has NEW UPGRADES to suit the diverse information needs of individual, investor, corporate and institutional readers. Subscribers now can obtain sitewide access via html as well as the convenience of individual delivery via PDF.
- SciBX is now available as a full text html site for institutions keen to provide access via a sitewide license. For librarians serving academic and corporate research institutions, the new html site is integrated with the familiar services provided through www.nature.com and can be viewed without charge for a limited time.
View the full text SciBX html site through www.nature.com. VIEW
- All SciBX articles have been integrated into BioCentury's Business Intelligence Platform via the newly upgraded BioCentury Archives 4.0. Individual subscribers and group accounts who receive the PDF version now can combine the entire BioCentury family of publications to conduct product, competitive and investment analysis.
View SciBX PDFs and the BioCentury Archives 4.0. VIEW
- Free trials of SciBX are available in either format. Please contact Subscriber Services for more information.
Order a Free Trial of SciBX. ORDER
If you're serious about translating science into medicines, then you need SciBX.
Week of 20.11.08
To access this content, select one of the VIEW buttons above.
Analysis
Cover story
Testing Parkinson's metal
Two multinational research teams have made a case for blocking iron accumulation in the brain to treat Parkinson's disease—a finding that could provide a path for creating disease-modifying PD drugs. The studies support the strategy taken by Prana Biotechnology, which is developing metal-binding compounds for PD.
Targets & Mechanisms
A structural fix for DMD
UCLA researchers have found that increasing expression of the structural protein sarcospan improves dystrophic pathology in mice with Duchenne muscular dystrophy. The question is whether increasing sarcospan will only slow muscle degeneration, and thus simply delay progression of the disease.
Tools
Micromanaging oncolytic viruses
Two research teams have applied a microRNA-based strategy for restricting the replication of oncolytic viruses to their target tumors. The approach seeks to avoid attenuation of the viral genome, a currently used technique that has so far avoided off-target effects but also limited the effectiveness of these agents as cancer therapies.
Fragment-based reality check
Burnham researchers have developed a fragment-based approach to lead discovery that identifies inhibitors of protein-protein interactions faster and more efficiently than computational or synthetic methods alone.
The Distillery
- BIK activators for cancer
- Small molecule tyrosine kinase inhibitors for diabetes
- Antioxidants and CHOP inhibitors for hemophilia A
- Cytokine stimulators for inflammation
- PRODH inhibitors for schizophrenia
- And more ...
- Hydrogel-based microcontact printing of membrane protein arrays
- Cell-based global protein stability profiling
- And more ...